Assistant Professor of @UMNHOT @UMNCancer. Former BMT Fellow @MayoClinic. Thoughts are my own.
Joined August 2022
- Tweets90
- Following100
- Followers73
- Likes28
Christopher Graham retweeted
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
Christopher Graham retweeted
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL.
In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵
ashpublications.org/bloodadv…
Christopher Graham retweeted
ASH welcomes its newly elected Executive Committee members! 👏
Bringing extensive experience and a shared commitment to advancing hematology, these leaders will help guide the Society's work in the years ahead.
Read the full announcement: ow.ly/1TWf5100YrV
Christopher Graham retweeted
In vivo CAR T: no apheresis, no manufacturing wait, no LD chemo.
Investigational LB2501 (CD19/CD20, @LegendBiotech) FIH, EHA 2026: DL2 ORR 6/6, CR 5/6, CRS gr1-2, no ICANS.
US IND now cleared. But n=6, 2.3 mo f/u: durability is the whole game.
#lymsm #CARTcells
Christopher Graham retweeted
Study found that coronary artery calcification identified during pretransplant evaluation predicted non-relapse mortality in patients receiving PTCy. Among elderly patients without known coronary artery disease, it was associated with inferior survival. ow.ly/p4rP50ZPM6U
Christopher Graham retweeted
The latest ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy has been published in Transplantation and Cellular Therapy, providing a standardized framework for grading toxicities associated with immune effector cell therapies. ,The guidance maintains and clarifies grading for CRS and ICANS, introduces modified ICE (M-ICE) for children and patients with developmental delays, and addresses emerging toxicities including hematotoxicity, IEC-HS and non-ICANS neurotoxicities.
📖 Read the full guideline: ow.ly/59na50ZOqrR
@ASTCT_Journal
Christopher Graham retweeted
CONGRESS | #ASH25 | PRESENTATION
Samer Srour presents preliminary data of a phase I trial evaluating Orca-Q with (n = 18) or without (n = 26) GvHD prophylaxis (tacrolimus) in patients receiving allo-HSCT with 8/8 HLA-matched donors. Removal of pharmacologic GvHD prophylaxis did not increase GvHD rates and may improve infection rates. At 12 months, cumulative incidence of Grade ≥3 #aGvHD was 8.4% in the prophylaxis cohort vs 5.6% in the without prophylaxis cohort; similarly, incidence of moderate–severe #cGvHD was 11.8% and 0%, respectively.
Follow our live feed for more updates: loom.ly/TJPbnGM
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress
@MDAndersonNews
Christopher Graham retweeted
Excited to share our abstract on cardiotoxicities with CAR-T therapy at #ASH25
Stop by poster #6301 to say hi 👋
@ChrisGrahamMD @SupriyaGuptaMD
Christopher Graham retweeted
Very proud to see our ARES study, demonstrating for the 1st time the efficacy of a fecal microbiota product in severe acute GVHD, featured in #ASH25 Newsdaily. More than a decade of rigorous research has now translated into a truly remarkable milestone. @MaaT_Pharma
Christopher Graham retweeted
CONGRESS | #ASH25 | PRESENTATION
Amandeep Salhotra shares results of a phase I trial of allogeneic CD6-CAR Tregs in patients with steroid-dependent or steroid-refractory #cGvHD (N = 6), noting that they can be successfully manufactured and cryopreserved. CD6-CAR Tregs cell infusion was not associated with significant toxicity, including CRS, ICANS, or GvHD flare.
Follow our live feed for more updates: loom.ly/TJPbnGM
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress @cityofhope
Christopher Graham retweeted
ICYMI: My piece covering Prof. Chiara Bonini’s inspiring Ham-Wasserman lecture was featured in today’s #ASHNewsDaily
Prof. Bonini took us through a journey in gene editing, innovation and the rapidly evolving future of cancer immunotherapy. 🧬
Grab your copy today!
#ASH25
Christopher Graham retweeted
Check out this #ASH25 special interest session on clonal hematopoesis today.
To all the GoT fans out there, here is our take covering the session highlights in today’s ASH Daily news!
@EmperorBlackMD @JoselleCookMD @ASH_hematology @CKBrierley @majorajay @ChrisGrahamMD @SupriyaGuptaMD
ashpublications.org/ashnewsd…
Christopher Graham retweeted
#ASHkudos to plenary from @KellyLBolton lab & collaborated @AbdelWahablab tackling THE most important clinical issue for our patients- potential prevention of t-MN by suppressing TP53 clonal expansion. A topic close to my heart. Onwards ! #ASH25
Christopher Graham retweeted
Great presentation by my colleague @SupriyaGuptaMD at #ASH25 👏
Allo CD19 CAR T azer-cel + low-dose SC IL-2 for LBCL relapsing after auto CAR T (n=12)
• ORR 75%, CR 50%
• CRS 67% (Gr 1–2), ICANS 17% (Gr 2–3), infections 33% (all Gr 2)
@ASHClinicalNews @ASH_hematology
Christopher Graham retweeted
CONGRESS | #ASH25 | PRESENTATION
Supriya Gupta presents findings from a phase I/Ib trial of azer-cel, an allogeneic CD19 CAR T-cell therapy + low-dose interleukin-2 (IL-2) in patients with LBCL who relapsed after autologous CAR T-cell therapy (N = 18).
Azer-cel + low-dose IL-2 showed a manageable safety profile with Grade 1–2 CRS reported in 72.2% of patients and Grade 1–3 ICANS in 16.7% of all patients. Among the efficacy set (n = 16), the ORR was 81.0% with a CR rate of 43.8%. Robust CAR T-cell expansion was observed among responders (n = 13).
Follow our live feed for more updates: loom.ly/POS6cqk
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @SupriyaGuptaMD @UMNHOT @UMNCancer
Christopher Graham retweeted
Join Prof. Chiara Bonini at the Ham Wasserman lecture today from 12:30 to 1:30 pm in West Hall D2 for an exciting presentation on how gene editing is reshaping cellular immunotherapy. #ASH25 #ASHNewsDaily @ASH_hematology
Christopher Graham retweeted
Excited to present our oral abstract at #ASH25 on the safety and efficacy of Azer-cel in LBCL in post-CAR-T relapse setting. Join me at 2:30 pm in West Hall D2. @TeamImugene
Christopher Graham retweeted
Ready to make the most of #ASH25? Follow these tips from the #ASHNewsDaily editorial board: ow.ly/AN9t50XvOUm 🧵
@JoselleCookMD @CKBrierley @ChrisGrahamMD @majorajay @SarahSewar @ZanwarSaurabh @SupriyaGuptaMD @EmperorBlackMD #ASHTrainee
1/2
Christopher Graham retweeted
Let @CKBrierley help you plan for a productive and calm #ASH25.
See Advice for a Young ASH Attendee: ow.ly/EWhr50XvOVy #ASHTrainee
2/2
